[Intravitreal bevacizumab for chronic central serous chorioretinopathy].
Central serous chorioretinopathy (CSCR) can lead to permanent visual loss in chronic cases. We report on a 57-year-old female patient with persistent findings over 6 months despite conservative therapy. A single intravitreal injection of bevacizumab led to a rapid morphologic and functional restitution without relapse or complication during the 19 weeks period after injection. Intravitreal injection of bevacizumab could be a therapeutic option for the treatment of chronic CSCR, however the results of appropriate studies must be awaited before it can be introduced into routine use.
Niegel
M F
MF
Augenklinik, Kliniken der Stadt Köln, Ostmerheimer Str. 200, 51109, Köln, Germany. niegelm@kliniken-koeln.de
Schrage
N F
NF
Christmann
S
S
Degenring
R F
RF
D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D002825:Chorioretinitis / Q000175:diagnosis / Q000188:drug therapy*; D005260:Female; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D006801:Humans; D007267:Injections; D008875:Middle Aged; D041623:Tomography, Optical Coherence; D014822:Vitreous Body
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab